Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803

Visit website

NEWS

FDA

Incyte’s Jakafi Snags FDA Approval for Treatment of Steroid-Refractory Acute GVHD

The approval of Jakafi marks the first approved treatment for this indication in the United States.

May 28, 2019

2 min read

Alex Keown

FDA

FDA Action Alert: Regeneron, Bristol-Myers Squibb and Incyte

May has been a fairly slow month for approvals by the U.S. Food and Drug Administration (FDA). There are currently only two scheduled for the rest of the month, with a third that has been withdrawn. Let’s take a look.

May 10, 2019

3 min read

Mark Terry

Job Trends

Biotech Companies Provide High Median Salaries, Analysis Shows

For young people looking to find a career path, the pharmaceutical industry is a good one to go into, especially if salary is a major concern.

May 9, 2019

2 min read

Alex Keown

FDA

FDA Action Alert: Alexion, Stemline Therapeutics and Incyte

Two of the three drugs that were up for review in mid- to late-February received much earlier approval in December 21, the day before the federal government shutdown. The shutdown ended on January 25, 2019.

February 15, 2019

4 min read

Mark Terry

Business

Lilly and Incyte’s Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials

The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.

February 4, 2019

2 min read

Alex Keown

Biotech Beach

Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.

November 30, 2018

3 min read

Mark Terry

Drug Development

Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies

Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday.

October 23, 2018

3 min read

Mark Terry

Business

Pharma and Biotech Companies Provide Top Salaries: Survey

This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or biotech industries.

August 6, 2018

2 min read

Alex Keown

Drug Development

Incyte Plans sNDA for Impressive Jakafi but Forced to Scrap Another Program

Shares of Incyte Corporation are up slightly this morning after the company started off its annual R&D day with positive news from its pivotal REACH1 study of Jakafi (ruxolitinib) in steroid-refractory acute graft-versus-host disease (GVHD) and sets up the filing of a supplemental New Drug Application.

June 21, 2018

2 min read

AWARDS